Category: Alzheimer’s disease

TRAILBLAZER-ALZ3

A recurring theme of my blog has been that our best shot at attacking Alzheimer’s disease is in the earliest stage, before cognitive impairment has started. We now know that the first pathological signs...

Pushback against aducanumab (Aduhelm)

As reported in the New York Times today, two prominent American medical institutions, the Cleveland Clinic and the Mt. Sinai Health System in New York, have announced that they will not allow administration of...

The cost of aducanumab

When donepezil (Aricept) was approved in 1996, it was the first tolerable drug available to treat the cognitive symptoms of Alzheimer’s disease. I remember being shocked that the price was so high, about $120...

Aducanumab controversies

Yesterday I participated in a panel discussion regarding recommendations for use of aducanumab, now called by the proprietary name Aduhelm, in the treatment of Alzheimer’s disease. The conference, Dialogue: Current Perspectives on Aducanumab, was sponsored...

Sensory triggers of memory

Marcel Proust famously wrote in his semi-autobiographical novel Remembrance of Things Past published in 1913 how the smell and taste of a tea-soaked madeleine cake evoked the childhood memory of breakfast with his Aunt Léonie. The...

FDA approves aducanumab

Today the FDA approved the use of Biogen’s anti-amyloid monoclonal antibody aducanumab for treating early-stage Alzheimer’s disease.  I have mixed feelings about this approval. As someone living with early-stage Alzheimer’s who participated in the aducanumab...